Felix von Haniel

Felix von Haniel has a diverse work experience spanning different industries and roles. Felix is currently working at Cyprotex as the SVP of Business Development, a position they have held since October 2021. Prior to that, they served as the VP Head of Business Development at Cyprotex from September 2019 to November 2021. In 2019, they also worked at Evotec as the SVP of Business Development.

Before entering the pharmaceutical and biotechnology sector, Felix held various positions in different companies. Felix was a Business Angel and Investor at Direct private investments starting from November 2012. From September 2017 to June 2019, they worked at Ncardia as the VP of Business Development and Sales, following a successful merger with Pluriomics.

Felix also has experience at Axiogenesis, where they served as the Commercial Director from an unknown start date to August 2017. Felix was responsible for global marketing and sales, as well as managing the company's IP portfolio. Prior to that, they held the position of Director and President at Horkla S.A. from November 2006 to October 2008.

Their earlier experiences include working as a Change Management Consultant at Antu Lemu S.A. from November 2005 to November 2006, as a Project Manager at Gemabiotech for drug discovery from an unknown start date to 2004, and as a Research Scientist at inta and max plank from 1998 to 2000, respectively.

Felix von Haniel earned a BSc in Molecular Biology from the University of Melbourne in 1995. Felix then pursued a Graduate Diploma in Biotechnology at the same university from 1996 to 1999. In 2004, they attended the University of Cambridge where they completed an MBA in International Business, Entrepreneurship, and Finance in 2005.